ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1611

Systemic Lupus Erythematosus Registries: Are the Measures Captured in the Real World Similar to Those in Clinical Trials?

Jennifer Lofland1, Eric Wan 2, Pamela Berry 3 and Chetan Karyekar 4, 1Janssen Scientific Affairs, LLC, Spring House, PA, 2Johns Hopkins Bloomberg School of Public Health, Spring House, PA, 3Janssen Scientific Affairs, LLC, Horsham, PA, 4Janssen Global Services, LLC, Horsham, PA

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: clinical trials and registries, Lupus, real-world

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 11, 2019

Title: SLE – Clinical Poster II: Comorbidities

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic, autoimmune disease that causes connective tissue inflammation and can result in multiple organ damage. Registries may be a valuable source of real-world data that complements randomized clinical trial data. 

To 1) identify SLE registries, 2) determine what measures are collected within the registries, and 3) determine which registries capture metric(s) and/or endpoints which have been collected within a SLE clinical trial. 

Methods: Utilizing the Preferred Reporting Items for Systematic reviews and Meta-Analysis (PRISM) guidelines, we conducted a systematic review of the literature search using PubMed, EMBASE, and Scopus databases between 2012 to the present and a gray literature search to identify SLE registries.  We reviewed each registry for the following criteria: 1) population diagnosed with SLE, who were 16 years or older; 2) published in English language; and 3) contained content on any of the following measures or endpoints; Short-Form(SF)-36, SRI (SLE responder index), SLEDAI (SLE Disease Activity Index), PGA (physician global assessment), BILAG (British Isles Lupus Activity Group), Systemic Lupus Collaborating Clinics (SLICC) damage index, Lupus Quality of Life (LupusQoL), Functional Assessment of Chronic Illness Therapy (FACIT)-fatigue, healthcare utilization, clinical outcomes (e.g. flares) or biobank information.

Results: A total of 41 SLE registries were identified.  No registry captures all the components of the SRI-4, the SLEDAI, BILAG, and PGA.  Ten registries collect 2 components of the SRI-4 (Table 1).  Four SLE registries capture the SF-36 and 3 registries collect biobank data (Table 1).    There is at least 1 SLE registry in each of the 4 main regions of the world; North America, Europe, Asia Pacific, and Latin America. 

Conclusion: There is variability among the measures collected by SLE registries.  Many of the SLE registries capture a subset of measures common to those collected by SLE clinical trials.  It appears that measures collected by SLE clinical trials are not necessarily the same as those captured in real world settings.  Additional research is needed to develop validated measures which may be captured within clinical trials as well as within real world settings such as registries.

Table 1: Overview of SLE Registries


Disclosure: J. Lofland, Janssen Scientific Affairs, LLC, 3; E. Wan, Janssen Scientific Affairs, LLC, 3, 9; P. Berry, Janssen Scientific Affairs, LLC, 3; C. Karyekar, Abbott, 3, BMS, 3, Janssen, 1, 3, Janssen Scientific Affairs, LLC, 3, Novartis, 3.

To cite this abstract in AMA style:

Lofland J, Wan E, Berry P, Karyekar C. Systemic Lupus Erythematosus Registries: Are the Measures Captured in the Real World Similar to Those in Clinical Trials? [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/systemic-lupus-erythematosus-registries-are-the-measures-captured-in-the-real-world-similar-to-those-in-clinical-trials/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/systemic-lupus-erythematosus-registries-are-the-measures-captured-in-the-real-world-similar-to-those-in-clinical-trials/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology